Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Next Previous
Trial Profile

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onvansertib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Cardiff Oncology

Most Recent Events

  • 16 Apr 2025 Status changed from recruiting to active, no longer recruiting, as per Cardiff Oncology media release.
  • 16 Apr 2025 According to a Cardiff Oncology media release, the patient enrollment has been completed in this trial and additional clinical data from this trial is expected in the first half of 2025.
  • 27 Feb 2025 According to a Checkpoint Therapeutics media release, company looking forward to sharing additional clinical updates from CRDF-004 in H1 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top